Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BHE202206

A SSRI & Partial 5-HT1A Agonist

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: A SSRI & Partial 5-HT1A Agonist
    Indications: Depression
    Research phase: Phase II/ III
    Cooperation demands: License-out or co-development
  • Highlights



    1. Serotonin transporters(SERTs) and serotonin 5-HT1A are occupied after administration of Serotonin Partial Agonist Reuptake Inhibitor(SPARI) .


    2. Serotonin level increases initially in the somatodendritic areas of the serotonin neuron due to the blockage of the serotonin transporter (SERTs).


    3. After increment of serotonin in the somatodendritic areas of the serotonin neuron, somatodendritic 5-HT1A autoreceptors de-sensitize or down-regulate.


    4. As a result of the somatodendritic receptors’ down-regulation, inhibition of impulse flow in the serotonin neuron never exists. Therefore, serotonin is released in the axon terminal when the neuronal impulse flow restarted.

  • Project Introduction

    1. Asset type: SSRI & Partial 5-HT1A Agonist

    2. Indication: Depression

    3. Modality: Small molecular

    4. Research phase: Phase II/ III

    5. Cooperation demands: License-out or co-development

    6. Research progress:

    (1) Compared with the benchmark molecule Vilazodone, this asset demonstrated a better clinical PK profile at the same dose level. And based on the BBB data in animals, the concentration of this asset in human CSF will be much higher than that of Vilazodone. Phase I clinical results showed that the incidence of gastrointestinal side effects was lower than that from Vilazodone.
    (2) Phase III clinical research is ongoing in China.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message